An open label, multi-center, phase II study to investigate the safety and efficacy of SDX-101 (R-Etodolac) in patients with relapsed or refractory multiple myeloma (MM).

Trial Profile

An open label, multi-center, phase II study to investigate the safety and efficacy of SDX-101 (R-Etodolac) in patients with relapsed or refractory multiple myeloma (MM).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs SDX 101 (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top